Immunic Free Cash Flow vs Average Equity Analysis

IMUX Stock  USD 1.30  0.02  1.56%   
Trend analysis of Immunic balance sheet accounts such as Other Current Liabilities of 19.9 M or Total Current Liabilities of 26 M provides information on Immunic's total assets, liabilities, and equity, which is the actual value of Immunic to its prevalent stockholders. By breaking down trends over time using Immunic balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.

About Immunic Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Immunic at a specified time, usually calculated after every quarter, six months, or one year. Immunic Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Immunic and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Immunic currently owns. An asset can also be divided into two categories, current and non-current.

Immunic Balance Sheet Chart

Immunic Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Immunic uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Immunic's Short Term Debt is fairly stable compared to the past year. Non Current Liabilities Other is likely to rise to about 1.2 M in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 955.9 K in 2024.

Total Assets

Total assets refers to the total amount of Immunic assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Immunic books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Immunic balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Immunic are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Most indicators from Immunic's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunic current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.Selling General Administrative is likely to drop to about 14 M in 2024. Issuance Of Capital Stock is likely to drop to about 810.4 K in 2024
 2021 2022 2023 2024 (projected)
Net Interest Income66K1.0M3.1M3.2M
Interest Income66K1.0M3.1M3.2M

Immunic fundamental ratios Correlations

0.310.210.390.960.21-0.95-0.040.570.960.60.960.41-0.620.550.33-0.530.210.97-0.23-0.48-0.530.280.280.340.05
0.310.630.690.21-0.04-0.31-0.580.20.34-0.160.370.82-0.220.380.560.05-0.040.39-0.030.06-0.450.560.560.47-0.51
0.210.630.920.120.28-0.27-0.60.410.33-0.320.330.74-0.410.060.4-0.070.280.31-0.18-0.38-0.40.590.60.28-0.56
0.390.690.920.270.09-0.34-0.60.390.410.00.40.91-0.460.390.45-0.080.090.42-0.07-0.42-0.560.570.580.31-0.46
0.960.210.120.270.28-0.94-0.040.550.930.590.920.26-0.750.510.38-0.730.280.93-0.14-0.6-0.550.330.320.180.03
0.21-0.040.280.090.28-0.430.060.670.42-0.380.41-0.19-0.34-0.090.04-0.351.00.37-0.58-0.320.240.190.190.17-0.11
-0.95-0.31-0.27-0.34-0.94-0.430.03-0.68-0.99-0.39-0.99-0.290.63-0.41-0.340.56-0.43-0.980.340.490.44-0.36-0.36-0.360.05
-0.04-0.58-0.6-0.6-0.040.060.030.13-0.070.24-0.07-0.640.4-0.24-0.880.190.06-0.09-0.150.30.64-0.83-0.840.120.86
0.570.20.410.390.550.67-0.680.130.690.030.670.21-0.440.19-0.03-0.330.670.65-0.33-0.41-0.180.240.240.30.01
0.960.340.330.410.930.42-0.99-0.070.690.380.990.36-0.640.420.35-0.540.420.99-0.34-0.5-0.470.380.380.36-0.08
0.6-0.16-0.320.00.59-0.38-0.390.240.030.380.350.12-0.270.430.02-0.3-0.380.390.27-0.33-0.43-0.19-0.2-0.030.53
0.960.370.330.40.920.41-0.99-0.070.670.990.350.37-0.630.430.35-0.530.411.0-0.36-0.44-0.450.370.370.38-0.09
0.410.820.740.910.26-0.19-0.29-0.640.210.360.120.37-0.330.520.530.03-0.190.40.03-0.2-0.620.510.520.39-0.43
-0.62-0.22-0.41-0.46-0.75-0.340.630.4-0.44-0.64-0.27-0.63-0.33-0.34-0.550.92-0.34-0.63-0.120.870.67-0.56-0.570.20.32
0.550.380.060.390.51-0.09-0.41-0.240.190.420.430.430.52-0.340.4-0.22-0.090.51-0.06-0.2-0.420.320.320.23-0.18
0.330.560.40.450.380.04-0.34-0.88-0.030.350.020.350.53-0.550.4-0.420.040.380.04-0.39-0.70.860.860.0-0.73
-0.530.05-0.07-0.08-0.73-0.350.560.19-0.33-0.54-0.3-0.530.030.92-0.22-0.42-0.35-0.52-0.160.790.51-0.39-0.380.360.16
0.21-0.040.280.090.281.0-0.430.060.670.42-0.380.41-0.19-0.34-0.090.04-0.350.37-0.58-0.320.240.190.190.17-0.11
0.970.390.310.420.930.37-0.98-0.090.650.990.391.00.4-0.630.510.38-0.520.37-0.35-0.45-0.470.370.380.4-0.09
-0.23-0.03-0.18-0.07-0.14-0.580.34-0.15-0.33-0.340.27-0.360.03-0.12-0.060.04-0.16-0.58-0.35-0.17-0.430.050.06-0.68-0.04
-0.480.06-0.38-0.42-0.6-0.320.490.3-0.41-0.5-0.33-0.44-0.20.87-0.2-0.390.79-0.32-0.45-0.170.59-0.45-0.450.30.18
-0.53-0.45-0.4-0.56-0.550.240.440.64-0.18-0.47-0.43-0.45-0.620.67-0.42-0.70.510.24-0.47-0.430.59-0.68-0.690.240.45
0.280.560.590.570.330.19-0.36-0.830.240.38-0.190.370.51-0.560.320.86-0.390.190.370.05-0.45-0.681.0-0.08-0.87
0.280.560.60.580.320.19-0.36-0.840.240.38-0.20.370.52-0.570.320.86-0.380.190.380.06-0.45-0.691.0-0.08-0.87
0.340.470.280.310.180.17-0.360.120.30.36-0.030.380.390.20.230.00.360.170.4-0.680.30.24-0.08-0.080.15
0.05-0.51-0.56-0.460.03-0.110.050.860.01-0.080.53-0.09-0.430.32-0.18-0.730.16-0.11-0.09-0.040.180.45-0.87-0.870.15
Click cells to compare fundamentals

Immunic Account Relationship Matchups

Immunic fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets66.0M167.9M139.1M127.8M54.3M81.3M
Other Current Liab343K4.7M585K8.2M18.9M19.9M
Total Current Liabilities7.1M8.4M11.4M13.1M24.7M26.0M
Total Stockholder Equity58.4M158.8M127.1M113.7M28.9M27.5M
Property Plant And Equipment Net713K1.1M1.1M1.8M1.8M1.4M
Net Debt(28.8M)(126.8M)(86.3M)(105.2M)(45.3M)(47.6M)
Retained Earnings(59.9M)(103.9M)(196.9M)(317.3M)(410.9M)(390.3M)
Accounts Payable2.4M3.7M3.7M4.3M5.1M3.9M
Cash29.4M127.5M86.9M106.7M46.7M64.0M
Non Current Assets Total33.7M34.1M34.1M1.9M1.8M1.7M
Cash And Short Term Investments29.4M127.5M86.9M116.4M46.7M66.0M
Common Stock Shares Outstanding7.7M15.7M23.7M31.8M44.3M46.5M
Liabilities And Stockholders Equity66.0M167.9M139.1M127.8M54.3M81.3M
Non Current Liabilities Total520K679K584K992K639.0K607.0K
Other Current Assets2.9M1.2M18.1M9.5M5.2M4.1M
Other Stockholder Equity53.7M266.8M324.2M427.9M436.1M245.3M
Total Liab7.6M9.1M12.0M14.1M25.4M26.6M
Property Plant And Equipment Gross713K1.1M1.1M1.8M1.8M1.4M
Total Current Assets32.2M133.7M105.0M125.9M52.5M70.8M
Accumulated Other Comprehensive Income(1.4M)(4.1M)(252K)3.0M3.8M3.9M
Non Currrent Assets Other108K37K42K43K38.7K36.8K
Net Tangible Assets25.4M125.8M94.1M113.7M130.7M80.6M
Retained Earnings Total Equity(59.9M)(103.9M)(196.9M)(317.3M)(285.6M)(299.8M)
Capital Surpluse119.6M266.8M324.2M427.9M492.1M326.3M
Non Current Liabilities Other520K679K584K992K1.1M1.2M
Property Plant Equipment80K203K1.1M294K264.6K251.4K
Other Assets37K42K943K43K49.5K47.0K
Net Receivables408K1.6M2.2M2.7M703K1.3M
Net Invested Capital58.4M158.8M127.1M113.7M28.9M27.5M
Net Working Capital25.2M125.3M93.6M112.8M27.8M26.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Immunic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunic Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Immunic Stock analysis

When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Fundamental Analysis
View fundamental data based on most recent published financial statements
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.11)
Return On Assets
(0.68)
Return On Equity
(1.31)
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.